Depomed (DEPO) Tops Q4 EPS by 12c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
- Wall St set to fall at open as yields and oil rebound; Fed minutes in focus
- Want to be a stock market bear? BCA says watch potential U.S. tax increases
- SpaceX seeks $40bn in financing for Nvidia chip purchase
- Musk rules out TSMC role in Terafab operations; Intel gains
- U.S. 10-year yield climb revives dotcom-era parallels: UBS weighs in
- HubSpot to cut 7% of workforce in restructuring plan
- Caribou Biosciences to halt CAR-T programs, explore sale
- Emera and Canadian Utilities agree to merge in $72B all-share deal
- Stryker names Spencer Stiles as CEO, Lobo moves to chair
- S&P 500, Nasdaq reach record closing highs as focus pivots to earnings
RBC Reiterates Sector Perform Rating and $22 PT on Depomed (DEPO) Following 4Q Results, Ahead of 2/23 RBC Healthcare Conference
February 22, 2017 7:42 AM ESTRBC Capital Markets analyst Randall Stanicky reiterates Sector Perform rating and $22 price target on Depomed Inc. (NASDAQ: DEPO), suggesting the strategic outlook remains the focus, as the company reported 2016 fourth quarter revenue and EPS slightly above consensus. RBC Capital Markets will be hosting Depomed at the RBC Healthcare Conference on Thursday,... More



